[go: up one dir, main page]

MA27794A1 - Dihydroquinazolines substituees a proprietes antivirales - Google Patents

Dihydroquinazolines substituees a proprietes antivirales

Info

Publication number
MA27794A1
MA27794A1 MA28581A MA28581A MA27794A1 MA 27794 A1 MA27794 A1 MA 27794A1 MA 28581 A MA28581 A MA 28581A MA 28581 A MA28581 A MA 28581A MA 27794 A1 MA27794 A1 MA 27794A1
Authority
MA
Morocco
Prior art keywords
antiviral properties
dihydroquinazolines
substituted
substituted dihydroquinazolines
preparation
Prior art date
Application number
MA28581A
Other languages
English (en)
Inventor
Tobias Wunberg
Judith Baumeister
Ulrich Betz
Mario Jeske
Thomas Lampe
Susanne Nikolic
Juergen Reefschlaeger
Rudolf Schohe-Loop
Frank Suessmeier
Holger Zimmermann
Rolf Grosser
Kerstin Henninger
Guy Hewlett
Joerg Keldenich
Dieter Lang
Peter Nell
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33305099&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27794(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of MA27794A1 publication Critical patent/MA27794A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Dihydroquinazolines substituées à propriétés antivirales L'invention se rapporte à des dihydroquinazolines substituées et aux procédés de leur préparation et également à leur utilisation dans la préparation de médicaments pour le traitement et/ou la prophylaxie des maladies, en particulier pour leur utilisation comme agents antiviraux, en particulier contre les cytomégalovirus.
MA28581A 2003-05-02 2005-11-08 Dihydroquinazolines substituees a proprietes antivirales MA27794A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10319612A DE10319612A1 (de) 2003-05-02 2003-05-02 Substituierte Dihydrochinazoline

Publications (1)

Publication Number Publication Date
MA27794A1 true MA27794A1 (fr) 2006-03-01

Family

ID=33305099

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28581A MA27794A1 (fr) 2003-05-02 2005-11-08 Dihydroquinazolines substituees a proprietes antivirales

Country Status (38)

Country Link
US (4) US7196086B2 (fr)
EP (1) EP1622880B3 (fr)
JP (1) JP4733631B2 (fr)
KR (1) KR100927063B1 (fr)
CN (1) CN100393706C (fr)
AR (1) AR044078A1 (fr)
AT (1) ATE355280T1 (fr)
AU (1) AU2004233978B2 (fr)
BR (1) BRPI0410029B8 (fr)
CA (1) CA2524069C (fr)
CL (1) CL2004000930A1 (fr)
CO (1) CO5700764A2 (fr)
CY (2) CY1106476T1 (fr)
DE (2) DE10319612A1 (fr)
DK (1) DK1622880T6 (fr)
EC (1) ECSP056138A (fr)
EG (1) EG25273A (fr)
ES (1) ES2284007T7 (fr)
FR (1) FR18C1029I2 (fr)
HN (1) HN2004000146A (fr)
HU (2) HUS1800018I1 (fr)
IL (1) IL171513A (fr)
MA (1) MA27794A1 (fr)
MX (1) MXPA05011707A (fr)
MY (1) MY144616A (fr)
NL (1) NL300933I2 (fr)
NO (2) NO333265B3 (fr)
NZ (1) NZ543317A (fr)
PE (1) PE20050145A1 (fr)
PL (1) PL1622880T6 (fr)
PT (1) PT1622880E (fr)
RU (1) RU2360912C2 (fr)
SI (1) SI1622880T1 (fr)
TW (1) TWI335912B (fr)
UA (1) UA82519C2 (fr)
UY (1) UY28294A1 (fr)
WO (1) WO2004096778A1 (fr)
ZA (1) ZA200508710B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10319612A1 (de) 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
DE10305785A1 (de) * 2003-02-12 2004-08-26 Bayer Healthcare Ag Dihydrochinazoline
DE10320780A1 (de) 2003-05-09 2005-01-20 Bayer Healthcare Ag Heterocyclyl-substituierte Dihydrochinazoline
DE10352499A1 (de) * 2003-11-11 2005-06-09 Bayer Healthcare Ag Substituierte Dihydrochinazoline II
DE102004022672A1 (de) 2004-05-07 2005-11-24 Bayer Healthcare Ag Substituierte Azachinazoline
DE102005027517A1 (de) * 2005-06-15 2006-12-21 Bayer Healthcare Ag Verfahren zur Herstellung von Dihydrochinazolinen
DE102011101446A1 (de) * 2011-05-10 2012-11-15 Aicuris Gmbh & Co. Kg Herstellung von "Dense Bodies" (DB)
DE102012101680A1 (de) 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
DE102012101659A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
DE102012101673A1 (de) 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
HUE043721T2 (hu) * 2013-06-19 2019-09-30 Aicuris Anti Infective Cures Gmbh Amorf letermovir és szilárd gyógyászati készítményei orális adagolásra
US9890128B2 (en) 2013-12-12 2018-02-13 Merck Sharp & Dohme Corp. Process for making substituted quinazoline compounds
WO2017091453A1 (fr) * 2015-11-24 2017-06-01 Merck Sharp & Dohme Corp. Nouveaux procédés de production de composés de quinazoline substitués à l'aide de catalyseurs de liaison hydrogène
EP3498715B1 (fr) * 2016-08-08 2021-06-09 Medshine Discovery Inc. Composé anti virus hcmv
AU2019218150B2 (en) * 2018-02-08 2021-05-13 Phaeno Therapeutics Co., Ltd. Crystal form of 3,4-dihydrothieno[3,2-d]pyrimidine compound and preparation method therefor
EP3527209A1 (fr) * 2018-02-16 2019-08-21 UCB Biopharma SPRL Dérivés pharmaceutiques de noyau hétérobicyclique 6,5
TWI838401B (zh) 2018-09-12 2024-04-11 瑞士商諾華公司 抗病毒性吡啶并吡𠯤二酮化合物
TWI867053B (zh) 2019-09-26 2024-12-21 瑞士商諾華公司 抗病毒吡唑并吡啶酮化合物
UY39099A (es) 2020-02-27 2021-08-31 Aic246 Gmbh & Co Kg 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio y composiciones farmacéuticas del mismo
AR121440A1 (es) 2020-02-27 2022-06-08 Aic246 Gmbh & Co Kg Un método de preparación de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio monohidrato, dicho compuesto y el uso del mismo para el tratamiento de infecciones virales
UY39097A (es) 2020-02-27 2021-09-30 Aic246 Gmbh & Co Kg Sal de potasio del ácido 2-[(4s)-8-fluoro-2-[4-(3- metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il]acético
UY39095A (es) 2020-02-27 2021-09-30 Aic246 Gmbh & Co Kg Composiciones farmacéuticas que comprenden acetato de 2- [(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il] e iones de sodio
AR121439A1 (es) * 2020-02-27 2022-06-08 Aic246 Gmbh & Co Kg Un método para producir una forma cristalina de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il]acetato de sodio trihidrato
EP3906929A1 (fr) 2020-05-08 2021-11-10 AiCuris GmbH & Co. KG Letermovir pour son utilisation dans la prévention et le traitement des infections à coronavirus
WO2022038457A1 (fr) 2020-08-17 2022-02-24 Lupin Limited Procédé de précipitation de letermovir amorphe
CN115403528B (zh) * 2021-05-27 2025-01-07 南京正大天晴制药有限公司 无定形3,4-二氢喹唑啉衍生物的制备方法
CN114031560B (zh) * 2021-11-16 2022-10-04 山东诚创蓝海医药科技有限公司 一种来特莫韦钠盐的制备方法
AR128035A1 (es) 2021-12-21 2024-03-20 Aic246 Ag & Co Kg Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] e iones de potasio
WO2023185597A1 (fr) * 2022-04-01 2023-10-05 上海迪赛诺化学制药有限公司 Intermédiaire de letermovir et son procédé de préparation
CN115322157B (zh) * 2022-06-02 2023-12-05 浙江车头制药股份有限公司 来特莫韦中间体化合物及其制备方法和应用
CN117229223A (zh) * 2022-06-08 2023-12-15 苏州远智医药科技有限公司 一种杂环衍生物及其药物组合物、应用
TW202535393A (zh) 2023-12-21 2025-09-16 德商Ａｉｃ246股份兩合公司 2-[(4r,s)-8-氟-2-[4-(3-甲氧基苯基)哌嗪-1-基]-3-[2-甲氧基-5-(三氟甲基)苯基]-3,4-二氫喹唑啉-4-基]乙酸之非鏡像異構物胺基醇鹽及胺基醚鹽及其於鏡像異構物分離之用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4320347A1 (de) 1993-06-19 1994-12-22 Boehringer Mannheim Gmbh Quinazolin-Derivate und diese enthaltende Arzneimittel
US5854245A (en) * 1996-06-28 1998-12-29 Merck & Co., Inc. Fibrinogen receptor antagonists
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
DE19802437A1 (de) 1998-01-23 1999-07-29 Bayer Ag Verwendung von substituierten Sulfonamiden als anitvirale Mittel und neue Stoffe
ATE245641T1 (de) 1998-02-17 2003-08-15 Tularik Inc Antivirale pyrimidinderivate
WO2000063194A1 (fr) 1999-04-19 2000-10-26 Shionogi & Co., Ltd. Derives de sulfonamide possedant des noyaux oxadiazole
DE19930075A1 (de) 1999-06-30 2001-01-04 Bayer Ag Neue Amino- und Amidosulfonamide als antivirale Mittel
US6730682B2 (en) * 2000-07-12 2004-05-04 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
EP1325008B1 (fr) * 2000-07-31 2005-10-05 F. Hoffmann-La Roche Ag Derives de la piperazine
EP1201765A3 (fr) * 2000-10-16 2003-08-27 Axxima Pharmaceuticals Aktiengesellschaft Kinases cellulaires impliqués dans l'infection par cytomégalovirus et leur inhibition
HUP0303813A3 (en) 2001-04-19 2005-05-30 Bayer Ag Arylsulfonamides as antiviral agents, process for preparation of the compounds and pharmaceutical compositions containing them
DE10138578A1 (de) 2001-08-06 2003-02-27 Bayer Ag Heterocyclylarylsulfonamide
DE10251914A1 (de) 2002-11-08 2004-05-19 Bayer Ag Substituierte Chinazoline
DE10319612A1 (de) 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
DE10305785A1 (de) * 2003-02-12 2004-08-26 Bayer Healthcare Ag Dihydrochinazoline
DE10320780A1 (de) * 2003-05-09 2005-01-20 Bayer Healthcare Ag Heterocyclyl-substituierte Dihydrochinazoline
DE10352499A1 (de) * 2003-11-11 2005-06-09 Bayer Healthcare Ag Substituierte Dihydrochinazoline II
KR100610731B1 (ko) 2004-02-24 2006-08-09 한국과학기술연구원 Ｔ-형 칼슘 채널 차단제로서 유용한 ３,４-디히드로퀴나졸린유도체 및 그의 제조 방법
DE102004022672A1 (de) * 2004-05-07 2005-11-24 Bayer Healthcare Ag Substituierte Azachinazoline
KR20080009048A (ko) * 2005-01-25 2008-01-24 프롤렉시스 파마슈티칼스, 인크. 항종양제로서 퀴녹살린 유도체
DE102005027517A1 (de) 2005-06-15 2006-12-21 Bayer Healthcare Ag Verfahren zur Herstellung von Dihydrochinazolinen
BRPI0613604A2 (pt) * 2005-07-21 2011-01-18 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por inibidores de ptp-1b, e utilização dos compostos
DE102006009928A1 (de) 2006-03-03 2007-09-06 Aicuris Gmbh & Co. Kg Substituierte Arylsulfonamide
DE102012101680A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
DE102012101659A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
DE102012101673A1 (de) 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
HUE043721T2 (hu) * 2013-06-19 2019-09-30 Aicuris Anti Infective Cures Gmbh Amorf letermovir és szilárd gyógyászati készítményei orális adagolásra

Also Published As

Publication number Publication date
BRPI0410029A (pt) 2006-04-25
USRE49698E1 (en) 2023-10-17
ZA200508710B (en) 2006-12-27
USRE46791E1 (en) 2018-04-17
AU2004233978A1 (en) 2004-11-11
KR20060009883A (ko) 2006-02-01
FR18C1029I2 (fr) 2020-07-17
US20050065160A1 (en) 2005-03-24
NO20055649L (no) 2006-01-31
PL1622880T6 (pl) 2018-08-31
WO2004096778A1 (fr) 2004-11-11
UA82519C2 (uk) 2008-04-25
HK1092463A1 (zh) 2007-02-09
NO333265B3 (no) 2019-06-03
US20070191387A1 (en) 2007-08-16
HUS1800028I1 (hu) 2018-07-30
ES2284007T3 (es) 2007-11-01
SI1622880T1 (sl) 2007-08-31
ES2284007T7 (es) 2018-06-20
EP1622880A1 (fr) 2006-02-08
CA2524069C (fr) 2011-11-08
PT1622880E (pt) 2007-06-04
HUS1800018I1 (hu) 2018-05-28
RU2360912C2 (ru) 2009-07-10
AU2004233978B2 (en) 2010-02-11
DK1622880T6 (da) 2018-06-18
US7196086B2 (en) 2007-03-27
PE20050145A1 (es) 2005-05-22
JP4733631B2 (ja) 2011-07-27
FR18C1029I1 (fr) 2018-08-17
CO5700764A2 (es) 2006-11-30
DK1622880T3 (da) 2007-06-25
TW200510343A (en) 2005-03-16
NO333265B1 (no) 2013-04-22
NO20055649D0 (no) 2005-11-30
JP2006525249A (ja) 2006-11-09
ECSP056138A (es) 2006-04-19
KR100927063B1 (ko) 2009-11-13
ATE355280T1 (de) 2006-03-15
CY1106476T1 (el) 2012-01-25
PL1622880T3 (pl) 2007-08-31
UY28294A1 (es) 2004-11-30
BRPI0410029B1 (pt) 2019-12-31
CY2018019I1 (el) 2018-12-12
US8513255B2 (en) 2013-08-20
CL2004000930A1 (es) 2005-03-18
EP1622880B3 (fr) 2018-05-23
CY2018019I2 (el) 2018-12-12
AR044078A1 (es) 2005-08-24
MY144616A (en) 2011-10-14
TWI335912B (en) 2011-01-11
BRPI0410029B8 (pt) 2021-06-15
RU2005137276A (ru) 2006-07-27
MXPA05011707A (es) 2006-02-13
DE10319612A1 (de) 2004-11-18
EP1622880B1 (fr) 2007-02-28
NL300933I2 (nl) 2018-04-26
CN1784390A (zh) 2006-06-07
CN100393706C (zh) 2008-06-11
HN2004000146A (es) 2008-06-24
NZ543317A (en) 2008-05-30
EG25273A (en) 2011-12-04
DE502004003052D1 (de) 2007-04-12
IL171513A (en) 2011-11-30
NO2018022I1 (no) 2018-07-04
CA2524069A1 (fr) 2004-11-11

Similar Documents

Publication Publication Date Title
MA27794A1 (fr) Dihydroquinazolines substituees a proprietes antivirales
MA33123B1 (fr) 2-acetamido-5-aryl-1,2,4-triazolones substitues et leur utilisation
MA30914B1 (fr) Dihydropyrazolones substituees utilisees dans le traitement de maladies cardiovasculaires et hematologiques.
AU2003291998A1 (en) Method and compositions for identifying anti-hiv therapeutic compounds
MY140488A (en) Substituted oxazolidinones and their use in the field of blood coagulation
MA31570B1 (fr) Oxazolidinones substitués et leur utilisation
MA31920B1 (fr) 4-(4-cyano-2-thioaryle)-dihydropyrimidinone et son utilisation
WO2004024097A8 (fr) Compositions et methodes de traitement de maladies de nature immune
MA31245B1 (fr) Amides de 4-aryl-1,4-dihydro-1,6-naphthyridine substitués et utilisation de ceux-ci
MY135766A (en) Quinolinones and naphthyridinones for treating inflammatory diseases
KR100521829B1 (en) Compositions and Methods for the Treatment of Alzheimer's Disease, Central Nervous System Injury, and Inflammatory Diseases
MA27556A1 (fr) Derives de phenylalanine comme inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete
AU2003297048A1 (en) Cyclohexyl compounds as ccr5 antagonists
GB2342717A (en) Methods for analyzing ltc4 synthase polymorphisms and diagnostic use
WO2005032471A3 (fr) Inhibiteurs de type benzylether et benzylamino de beta-secretase pour le traitement de la maladie d'alzheimer
AU2002307049A1 (en) Use of mglur5 antagonists in the manufacture of a medicament in the treatment of autism, mental retardation, schizophrenia
WO2003103732A3 (fr) Articles a base de polyolefine ayant des proprietes antimicrobiennes et leurs procedes de preparation
MA27305A1 (fr) Derives de 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene et leur utilisation en tant qu'inhibiteurs de renine dans le traitement de l'hypertension, de maladies cardiovasculaires ou renales
AU2003296992A1 (en) Pyrrolidine and azetidine compounds as ccr5 antagonists
AU2002248384A1 (en) Serpin drugs for treatment of hiv infection and method of use thereof
GB0111186D0 (en) Novel compounds
MA31535B1 (fr) (oxazolidinon-5-yl-méthyl)-2-thiophène-carboxamides substitués et leur utilisation dans le domaine de la coagulation sanguine
DE60313004D1 (de) Alpha-7-nikotinsäure-rezeptoragonisten und statine in kombination
MA30903B1 (fr) Derives de 2 - phenyl-6-minocarbonyl-pyrimidine
MA29625B1 (fr) Immunoglobulines